• M&A / Deals

Adcendo secures $75m in Series C funding for ADC development

pharminent April 15, 2026

• Commercial

J&J sets the tone for Q1 earnings with strong oncology growth

pharminent April 15, 2026

• Other

Amazon launches its AI drug discovery platform

pharminent April 15, 2026

• Regulatory

Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data

pharminent April 15, 2026

• M&A / Deals

Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico

pharminent April 15, 2026

• M&A / Deals

Parkinson’s charity partners Biognosys on biomarker project

pharminent April 15, 2026

• M&A / Deals

Daiichi exits OTC, with $1.55bn unit sale to Suntory

pharminent April 15, 2026

• M&A / Deals

BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut

pharminent April 15, 2026

• Manufacturing

Whitepaper: CDMOs at a Crossroads

pharminent April 15, 2026

• Policy / Pricing

Scientists issue call to arms over antifungal resistance

pharminent April 15, 2026

• Clinical Data

S16 Ep52: Medical Crossfire: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application

pharminent April 15, 2026

• Other

Amazon launches AI drug discovery platform

pharminent April 15, 2026

• Commercial

J&J leans on Tremfya, cancer drugs to overcome Stelara losses

pharminent April 14, 2026

• Commercial

With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026

pharminent April 14, 2026

• M&A / Deals

Lilly boosts ADC portfolio with CrossBridge Bio deal

pharminent April 14, 2026

• Manufacturing

Lilly investing billions to prepare for overseas oral GLP-1 launches

pharminent April 14, 2026

• Regulatory

FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development

pharminent April 14, 2026

• Regulatory

FDA renews criticism of trial sponsors over transparency

pharminent April 14, 2026

• Market Access

Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update

pharminent April 14, 2026

• M&A / Deals

Novo Nordisk partners OpenAI on R&D “transformation”

pharminent April 14, 2026

• Regulatory

Travere Therapeutics gains FDA approval for sparsentan in FSGS

pharminent April 14, 2026

• Regulatory

Travere Therapeutics gains FDA approval for sparsentan in FSGS

pharminent April 14, 2026

• Regulatory

MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority

pharminent April 14, 2026

• Regulatory

Travere claims first FDA OK in rare kidney disease FSGS

pharminent April 14, 2026

• Other

Novo Nordisk and OpenAI forge alliance to drive speedy drug development

pharminent April 14, 2026

• Clinical Data

Revolution rockets on strong pancreatic cancer data

pharminent April 14, 2026

• Regulatory

MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority

pharminent April 14, 2026

• Commercial

Alamar, Hemab, Kailera, and Seaport advance IPOs

pharminent April 14, 2026

• Clinical Data

Spyre drug for inflammatory bowel disease shows promise in early study

pharminent April 13, 2026

• Clinical Data

Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma

pharminent April 13, 2026

• Policy / Pricing

FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results

pharminent April 13, 2026

• Manufacturing

USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns

pharminent April 13, 2026

• Clinical Data

Allogene stock sails after CAR T clears residual lymphoma in early data cut

pharminent April 13, 2026

• Other

220: An Interview With Dr. Jaime Moore on Obesity Medications and Neuromuscular Disease

pharminent April 13, 2026

• Clinical Data

Revolution rises 40% as pancreatic cancer drug doubles survival

pharminent April 13, 2026

• Regulatory

IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy

pharminent April 13, 2026

• Clinical Data

IDEAYA/Servier PKC drug aces uveal melanoma trial

pharminent April 13, 2026

• M&A / Deals

AbbVie enters world of pain in up to $715M deal with China’s Haisco

pharminent April 13, 2026

• M&A / Deals

AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid

pharminent April 13, 2026

• Regulatory

FDA issues complete response letter to Replimune’s RP1 for melanoma

pharminent April 13, 2026